Revenue growth remains non-existent with a -100% historical contraction, while operating losses are exacerbated by significant stock-based compensation that reached $512,000 in 2025Q1.
| Sales/Revenue | 0 | 0 | 183K | 122K | 2.03M | 480K | 2.2M | 1.69M |
| Revenue Growth % | -100% | -100% | 50% | -93.99% | 322.71% | -78.19% | 30.62% | - |
| Cost of Goods Sold | 284K | 0 | 0 | 0 | 9.75M | 8.63M | 1.52M | 1.71M |
| COGS % of Revenue | - | - | - | - | 480.73% | 1797.29% | 69.29% | 101.66% |
| Gross Profit | -436K | 0 | 183K | 122K | -7.72M | -8.15M | 676K | -28K |
| Gross Margin % | - | - | 100% | 100% | -380.73% | -1697.29% | 30.71% | -1.66% |
| Gross Profit Growth % | - | -100% | 50% | 101.58% | 5.18% | -1305.18% | 2514.29% | - |
| Operating Expenses | 7.35M | 8.45M | 10.1M | 11.87M | 8.96M | 6.83M | 13.03M | 5.35M |
| OpEx % of Revenue | - | - | 5521.31% | 9727.87% | 441.6% | 1422.92% | 592.14% | 317.39% |
| Selling, General & Admin | 6.45M | 7.46M | 7.12M | 7.6M | 8.96M | 6.83M | 6.93M | 4.22M |
| SG&A % of Revenue | - | - | 3891.26% | 6231.15% | 441.6% | 1422.92% | 314.86% | 250.45% |
| Research & Development | 894K | 989K | 2.98M | 4.27M | 9.75M | 8.63M | 6.1M | 1.13M |
| R&D % of Revenue | - | - | 1630.05% | 3496.72% | 480.73% | 1797.29% | 277.28% | 66.94% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -9.75M | -8.63M | 31K | 0 |
| Operating Income | -7.49M | -8.45M | -9.92M | -11.75M | -16.68M | -14.98M | -12.36M | 5.38M |
| Operating Margin % | - | - | -5421.31% | -9627.87% | -822.33% | -3120.21% | -561.43% | 319.05% |
| Operating Income Growth % | - | 14.81% | 15.54% | 29.6% | -11.4% | -21.2% | -329.85% | - |
| EBITDA | -7.05M | -8.01M | -9.3M | -10.95M | -15.83M | -14.45M | -12.2M | 5.44M |
| EBITDA Margin % | - | - | -5081.42% | -8978.69% | -780.14% | -3011.25% | -554.34% | 322.85% |
| EBITDA Growth % | 51.78% | 13.83% | 15.11% | 30.8% | -9.51% | -18.47% | -324.28% | - |
| D&A (Non-Cash Add-back) | 439K | 439K | 622K | 792K | 856K | 523K | 156K | 64K |
| EBIT | -7.42M | 0 | -6.84M | -11.68M | -16.64M | -14.98M | -12.36M | -6.04M |
| Net Interest Income | -1.07M | 0 | -378K | 40K | -200K | -17K | 0 | 0 |
| Interest Income | 52K | 33K | 9K | 63K | 48K | 0 | 0 | 0 |
| Interest Expense | 1.08M | -1.13M | 387K | 23K | 248K | 17K | 0 | 69K |
| Other Income/Expense | -2.07M | 0 | 2.69M | 40K | -200K | 242K | 31K | -11.48M |
| Pretax Income | -9.56M | -2.89M | -7.23M | -11.71M | -16.89M | -14.73M | -12.33M | -6.11M |
| Pretax Margin % | - | - | -3951.91% | -9595.08% | -832.18% | -3069.79% | -560.02% | -362.55% |
| Income Tax | 0 | 0 | 0 | 0 | 330K | 0 | 31K | -595K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | -1.95% | 0% | -0.25% | 9.74% |
| Net Income | -9.56M | -2.89M | -7.23M | -11.71M | -17.21M | -14.73M | -12.36M | -5.51M |
| Net Margin % | - | - | -3951.91% | -9595.08% | -848.45% | -3069.79% | -561.43% | -327.24% |
| Net Income Growth % | -24.95% | 60.01% | 38.22% | 32% | -16.83% | -19.24% | -124.1% | - |
| Net Income (Continuing) | -9.56M | -2.89M | -7.23M | -11.71M | -17.21M | -14.73M | -12.36M | -5.51M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 549K | 549K | 549K | 549K | 549K | 549K | 0 | 0 |
| EPS (Diluted) | -0.00 | -1.30 | -23.10 | -37.50 | -55.50 | -47.70 | -31.50 | -14.10 |
| EPS Growth % | 80.36% | 94.37% | 38.4% | 32.43% | -16.35% | -51.43% | -123.4% | - |
| EPS (Basic) | - | -1.30 | -23.10 | -37.50 | -55.50 | -47.70 | -31.50 | -14.10 |
| Diluted Shares Outstanding | 4.49B | 2.23B | 313.27K | 311.9K | 310.4K | 309.13K | 392.2K | 387.93K |
| Basic Shares Outstanding | 4.49B | 2.23B | 313.27K | 311.9K | 310.4K | 309.13K | 392.2K | 387.93K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Immediate liquidity insolvency risk
As reported in financial statements, Abpro Holdings currently generates zero recurring revenue, with historical figures showing a -100% growth rate in recent periods, underscoring a business model entirely dependent on sporadic, milestone-based collaboration payments rather than a sustainable commercial product pipeline or predictable operational scale.
The absence of consistent top-line growth suggests that the company remains in a pre-commercial phase where financial viability is tied to binary clinical outcomes. Investors should monitor the reliance on partnership-driven inflows, as the lack of organic revenue streams necessitates constant capital market access to fund ongoing research activities.
Based on reported figures, the company's cost structure is dominated by R&D and SG&A expenses that consistently dwarf any sporadic revenue, with quarterly operating losses frequently exceeding $1 million, highlighting an unsustainable burn rate that appears to be rapidly depleting the firm's minimal cash reserves.
The concentration of expenses in clinical trial execution and administrative overhead indicates a high-fixed-cost model typical of early-stage biotech. Without a clear path to commercialization, the current expense discipline appears insufficient to preserve the company's limited liquidity, warranting significant concern regarding future operational continuity.
According to recent SEC filings, Abpro Holdings' net income is heavily impacted by non-cash items, including significant stock-based compensation reaching $512,000 in 2025Q1, which obscures the underlying cash-based operational losses and complicates the assessment of true economic performance for potential equity investors.
The reliance on equity-based incentives during periods of extreme cash scarcity suggests a strategy to preserve liquidity at the expense of shareholder dilution. Analysts should adjust for these non-cash charges to better understand the actual cash burn rate and the true extent of the company's financial distress.
As indicated by the reported cash balance of only $67,000, the company faces an existential liquidity threat that may force highly dilutive financing or asset liquidation, casting doubt on the long-term viability of the DiversImmune platform regardless of its theoretical technical advantages in bispecific antibody development.
While the platform technology may hold intrinsic value, the immediate balance sheet reality suggests that the company is in a precarious position that could lead to a total loss of equity value. Investors should interpret the current financial state as a critical indicator that the firm's survival is contingent upon immediate, non-dilutive capital infusions.
Quick answers to the most common questions about buying ABPWW stock.
For fiscal year 2025, Abpro Holdings Inc (ABPWW) reported total revenue of $0.0M. This represents a 100.0% decline compared to $1.7M in 2016.
Abpro Holdings Inc (ABPWW) reported a net loss of $2.9M for the fiscal year ending 2025.